Editor’s note

Thriving through change

A recently released analysis of the global courier industry from 2010-2021, shows that the pharmaceutical sector accounts for just seven per cent of the sector's global revenue stream, which was an estimated $3.55 billion in 2010

To switch or not to switch …

A notice dated March 30 from the Drug Controller General (India) asking for ‘science-based suggestions/ comments’ on the pros and cons of replacing animal-based gelatin capsules with cellulose-ba

Quality consciousness: A pre-requisite to progress

Manufacturing quality has now become probably the single most important concern in the boardrooms of pharmaceutical companies in India

Weeding out the bad FDCs

The fixed dose combination (FDC) issue has been a contentious one for years and on March 10 came back to haunt pharma companies in India

Once again, nothing much for pharma

In his third budget, Finance Minister Arun Jaitley has taken one more shot at a balancing act between maintaining fiscal discipline and loosening the purse strings to provide a growth impetus

Public health: In need of Nari Shakti

As we mark yet another Women’s Day this March, here are some sobering words from Sanghita Bhattacharyya, Senior Public Health Specialist at the Public Health Foundation of India

Revival mantras for MSMEs

Precious things come in small packages (think diamonds)

Acche Din Kab Aayenge?

All eyes are once again on India's Finance Minister Arun Jaitley as he prepares to present the Modi Government's second full budget

Online pharmacies both game changers and troublemakers

I’d hazard a guess that there is hardly anyone who is not a user of e-commerce platforms to ease the daily grind

WL dims Sun’s shine … a bit

A new year brings with it new hope but all indications are that 2016 is going to be a mixed bag for the pharmaceutical industry

Of laws and flaws

Could New Jersey Superior Court's decision this October be a wake up call for Indian companies with global ambitions

Sifting the trends into 2016

If the latest edition of the Antal Global Snapshot (AGS) on annual global hiring and firing trends is any indicator, hiring in India’s pharmaceutical industry is picking up and set to firm up in the

Will new IP policy ensure Sabka Vikas?

In our last issue, we highlighted Swati Spentose’s quiet rise to become a Rs 40-crore speciality API manufacturer

Finding the hidden gems

Vishal Jajodia could sign up as a poster boy for Prime Minister Narendra Modi's Make In India campaign

Balancing the scales

Besides the balanced reasoning within the Delhi HC judgement, it is the SC's intervention which could see this case go down as a major milestone

Mainstreaming AYUSH

The last month saw a major milestone in the patent versus patient debate

Playing for high stakes

According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a growth of 12 per cent, touching Rs 90,400 crores ($ 15 billion)

Mylan’s One Quality Standard a long way off

Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban

New strategies for growth

After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of light at the end of the R&D pipeline

Digital India: A new game needs new rules

With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology

Lee Pharma revives the CL debate

With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to pharmaceutical IP are gearing up for yet another discussion on this to

TRIPs-ing time again

When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug for the former

Data integrity … dil se

Two reports, released in early June, have both good news and bad news for the pharma industry in India

Wish list for PM Modi’s second year

Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the pharma sector as well Now that the milestone of PM Modi’s first year in office is over and done with, let&#

Income Tax Calculator, Budget 2019, How to Calculate Income Tax


Stock Market